ALC vs LLY
Valuation
Profitability
Growth
Financial Health
Dividends
AI Verdict
Alcon Inc. (ALC) exhibits a weak Piotroski F-Score of 4/9, indicating marginal financial health, while the absence of an Altman Z-Score prevents a full distress risk assessment. Despite solid revenue growth and strong gross margins, earnings are contracting year-over-year, and the stock trades at a high valuation (P/E 38.60 vs. sector average 212.00) with a weak technical trend. Analysts recommend a 'buy' with a $91.80 target, implying 14% upside, but this is at odds with deteriorating profitability and low insider sentiment. The Graham Number of $45.87 suggests significant overvaluation, though sector dynamics and growth expectations may justify some premium.
LLY shows neutral fundamentals based on deterministic rules. Financial strength is weak (F-Score 3/9). Mixed signals with both opportunities and risks present.
Compare Another Pair
Related Comparisons
ALC vs LLY: Head-to-Head Comparison
This page compares Alcon Inc. (ALC) and Eli Lilly and Company (LLY) across key fundamental metrics including valuation ratios, profitability margins, growth rates, financial health indicators, and dividend metrics. Each metric highlights the better-performing stock so you can quickly identify relative strengths and weaknesses.
Our AI engine independently analyzes each company's financials, competitive position, and market conditions to produce a verdict (Bullish, Neutral, or Bearish) along with key strengths and risks. Use this comparison alongside your own research to make informed investment decisions.